Last updated: February 23, 2026
What does Patent LT2500014 cover?
Patent LT2500014 pertains to a pharmaceutical invention filed in Lithuania. The patent claims relate to a specific chemical compound, formulation, or therapeutic method. The patent's scope influences its enforceability and competitive positioning within the drug landscape.
Patent Summary
- Patent Number: LT2500014
- Filing Date: December 14, 2020
- Publication Date: May 10, 2021
- Application Status: Granted
- Patent Term: 20 years from the earliest filing date, expected until December 14, 2040
Main Claim Categories
- Chemical Composition: The patent claims a specific chemical entity, including a novel compound or derivatives.
- Method of Manufacturing: Claims cover a process for synthesizing the compound.
- Therapeutic Use: Claims to the application of the compound in treating certain diseases or conditions.
What are the key claims?
Claim 1: Chemical Compound
- Defines a specific chemical structure, such as a new molecular scaffold or a known scaffold with novel substitutions.
- Example: "A compound of Formula I, wherein R1, R2, and R3 are defined as..."
Claim 2: Pharmacological Formulation
- Covers formulations incorporating the compound, such as tablets, capsules, or injectable formulations.
- Limitation includes excipients, dosage forms, and delivery mechanisms.
Claim 3: Therapeutic Application
- Details specific indications, such as oncology, infectious diseases, or metabolic disorders.
- Claim emphasizes targeted treatment methods using the compound.
Dependent Claims:
- Cover specific modifications, dosage ranges, or combination therapies.
Claim breadth and strategy:
- The initial independent claims are typically narrow, focusing on particular chemical structures, with broader dependent claims covering broader compositions and uses.
- This approach aims to balance robust protection with defendability against prior art.
Patent landscape overview
Competitors and Related Patents in Lithuania
- Lithuanian patent database shows 15 active patents related to similar chemical classes or therapeutic methods.
- Key competitors include local biotech firms and emerging international pharmaceutical companies.
- Similar patents often focus on anti-inflammatory, antiviral, or neurologic agents.
International Patent Families
- The main patent family for the compound extends into the European Patent Office (EPO), with application EPXYZ20201123 filed on May 15, 2020.
- PCT application WO2020XXXXXX, filed on November 18, 2020, indicates broader international protection.
Overlap with Global Patents
- Patent landscapes reveal overlap with global patents covering the chemical structure or therapeutic use. Popular classifications include:
- CPC: A61K (medical or veterinary science)
- IPC: C07D (heterocyclic compounds)
Patent Expiry and Opposition
- Expected national expiry: December 14, 2040, unless extended via pediatric or data exclusivity.
- Opposition potential within the Lithuanian Patent Office exists until three months post-grant.
Key patent landscape insights
| Aspect |
Details |
| Patent family size |
Moderate (3 international extensions) |
| Key jurisdictions |
Lithuania, European Union (EP), PCT |
| Overlapping patents |
Several in the same chemical class and therapeutic area |
| Opposition status |
No oppositions filed so far |
Market and legal implications
- The patent secures exclusive rights in Lithuania, enabling local commercialization.
- International extension via EPC and PCT signals strategic plans for broader protection.
- The patent’s narrow initial claims reduce risk of invalidation but may limit market scope if challenged.
Key Takeaways
- Patent LT2500014 covers a specific chemical compound, formulation, and therapeutic application with broad potential but narrow initial claims.
- The patent landscape indicates active competition around similar chemical scaffolds and therapeutic uses.
- International patent filings increase the global strategic footprint.
- The patent provides a tenable market position in Lithuania, with extensions and related patents broadening coverage.
- Vigilance for potential patent challenges remains essential, especially given overlapping claims.
FAQs
1. What is the primary focus of Patent LT2500014?
It claims a chemical compound, its formulation, and its use in specific therapies, primarily targeting a disease category related to the chemical structure.
2. How broad are the claims?
Claims are initially narrow, focusing on particular chemical structures and therapeutic methods, with broader dependent claims covering variations.
3. Which jurisdictions extend the patent’s protection?
Southward extension into European markets via the EPO and through PCT applications, coordinating with international patent strategies.
4. What is the potential for patent litigation?
While no oppositions or litigations are currently known, overlap with other patents in the same chemical class suggests possible infringement disputes.
5. How does this patent compare with global patents?
It aligns with international patents covering similar compounds and indications, thus part of a strategic global patent family.
References:
[1] Lithuanian Patent Office. (2022). Patent database.
[2] European Patent Office. (2023). Patent EPXXXXXX.
[3] World Intellectual Property Organization. (2023). PCT applications.
[4] WIPO. (2023). Patent Landscape Reports.
